World of DTC Marketing
JUNE 20, 2025
Low morale within the Food and Drug Administration (FDA) is more than just an internal issue—it sends shockwaves through the pharmaceutical industry, affecting regulatory timelines, decision-making, innovation, and public trust. When morale within such a crucial organization dips significantly, pharma companies should brace for turbulence and prepare for strategic adjustments.
Scienmag
JUNE 19, 2025
In the rapidly evolving landscape of immunotherapy, researchers have unveiled a strikingly innovative approach that could revolutionize how chimeric antigen receptor (CAR) T cells are generated and deployed to combat cancer and autoimmune diseases. This novel strategy circumvents the traditional, labor-intensive ex vivo manufacturing processes by enabling the generation of CAR T cells directly within the patient’s body.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT News
JUNE 20, 2025
Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one year, Vertex Pharmaceuticals said Friday. After three months, none of them suffered severe bouts of low blood sugar. After 12 months, out of the 12 participants, 10 no longer needed to inject insulin.
Rethinking Clinical Trials
JUNE 19, 2025
Speakers Stephanie Morain, PhD, MPH Associate Professor, Berman Institute of Bioethics & Department of Health Policy & Management Johns Hopkins University Nancy Kass, ScD Phoebe Berman Professor of Bioethics & Public Health Berman Institute of Bioethics & Department of Health Policy & Management Johns Hopkins University Ruth Faden, PhD, MPH Philip Franklin Wagley Professor of Biomedical Ethics Berman Institute of Bioethics &
Speaker: Brian Richardson, Brian Richardson, Founder and CEO of Richardson Consulting Group
Let’s face it—most ethics and compliance training programs aren’t winning awards for engagement. But that doesn’t mean they can’t be effective, captivating, and maybe even enjoyable! Join learning design expert Brian Richardson for a dynamic session on how to breathe new life into your ethics and compliance training. We'll explore innovative strategies to bring traditionally dry topics to life, making them resonate with learners and drive tangible change.
The Pharma Data
JUNE 20, 2025
Vertex Showcases Groundbreaking Data for Zimislecel in Type 1 Diabetes at ADA 85th Scientific Sessions Vertex Pharmaceuticals Incorporated has announced compelling new clinical data from its ongoing FORWARD-101 trial, underscoring the transformative potential of its investigational islet cell therapy, zimislecel (VX-880), in patients with type 1 diabetes (T1D).
Scienmag
JUNE 20, 2025
In a landmark advancement for cardiovascular science and patient care, the National Heart Centre Singapore (NHCS) and the Mayo Clinic have formalized a strategic partnership through a Memorandum of Understanding (MOU) aimed at catalyzing breakthroughs in cardiovascular research and innovation. This unprecedented collaboration seeks to leverage deep clinical insights and cutting-edge technologies to reshape the future landscape of cardiovascular medicine, with a particular emphasis on Asian popul
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Medical Xpress
JUNE 16, 2025
Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for leukemia significantly improves patient outcomes post-transplant, reducing the risk of the life-threatening complication of graft versus host disease (GVHD).
The Pharma Data
JUNE 15, 2025
Sanofi and Regeneron’s Dupixent Shows Superiority over Xolair in First-Ever Head-to-Head Phase 4 Study in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Co-existing Asthma Sanofi and Regeneron Pharmaceuticals, Inc. today presented new and significant data demonstrating the superiority of Dupixent® (dupilumab) over Xolair® (omalizumab) in a first-of-its-kind, head-to-head, Phase 4 study in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and co-existing asth
Scienmag
JUNE 16, 2025
A revolutionary innovation in medical diagnostics is on the horizon, poised to transform the way diseases such as cancer and neurodegenerative disorders are detected and monitored. Scientists at King’s College London have developed a groundbreaking nanoneedle patch, a device embedded with tens of millions of microscopic needles, each thousands of times thinner than a human hair.
Velocity Clinical Research
JUNE 15, 2025
At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights from our latest nationwide patient survey.
Advertisement
Enhancing Transparency & Efficiency Throughout the Trial Lifecycle for AI Readiness
Rethinking Clinical Trials
JUNE 16, 2025
The NIH Pragmatic Trials Collaboratory held its 2025 Annual Steering Committee Meeting in Bethesda, Maryland, on May 28 and 29. The program’s leadership discussed evolving approaches to pragmatic clinical trials and considered the latest developments in the landscape of pragmatic research. All materials from the meeting are now available online. The NIH Pragmatic Trials Collaboratory added 3 new trials in the past year.
The Pharma Data
JUNE 18, 2025
Phase 3 Trial Launches for Ifinatamab Deruxtecan in Advanced Prostate Cancer Patients Daiichi Sankyo and Merck have announced the initiation of IDeate-Prostate01 , a global Phase 3 clinical trial evaluating the investigational drug ifinatamab deruxtecan (I-DXd) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression during or following treatment with androgen receptor pathway inhibitors (ARPIs).
Scienmag
JUNE 19, 2025
In a groundbreaking advancement that promises to reshape the landscape of targeted drug delivery, scientists at Xi’an Jiaotong-Liverpool University (XJTLU) in collaboration with Nanjing University have engineered a novel nanoparticle system that significantly enhances the efficiency and safety of administering chemotherapy and potentially other therapeutic agents.
NPR Health - Shots
JUNE 18, 2025
A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries?
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Medical Xpress
JUNE 16, 2025
A new hereditary condition has been discovered that affects patients' ability to repair DNA—leaving them both at greater risk of developing blood cancer, and unable to repair some of the damage caused by chemotherapy treatments.
The Pharma Data
JUNE 15, 2025
Genmab Presents Positive Epcoritamab Combination Data in Relapsed or Refractory DLBCL Eligible for Autologous Stem Cell Transplantation Genmab A/S today shared new and highly promising data from its Phase 1b/2 EPCORE® NHL-2 trial (Arm 10, NCT04663347) evaluating its T-cell-engaging bispecific antibody, epcoritamab, in combination with rituximab, ifosfamide, carboplatin, and etoposide — a regimen collectively known as R-ICE — in adult patients with relapsed or refractory (R/R) diffuse large B-cel
Scienmag
JUNE 17, 2025
In a groundbreaking new study published in Pediatric Research , scientists have unlocked critical insights into the epigenetic regulation of Notch signaling pathways in persistent pulmonary hypertension of the newborn (PPHN), a devastating and often fatal condition affecting the pulmonary vasculature of neonates. This research profoundly deepens our understanding of the molecular choreography that governs disease progression and opens innovative avenues for targeted therapeutic interventions.
Bio Pharma Dive
JUNE 18, 2025
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Medical Xpress
JUNE 16, 2025
Two existing medications—one used for smoking cessation and the other for depression—appear to work effectively together in treating alcohol use disorder. The combination reduces alcohol cravings, lowers consumption, and may decrease the risk of nausea. These findings come from a new study led by the University of Gothenburg, Sweden.
The Pharma Data
JUNE 15, 2025
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update for ELEVIDYS (delandistrogene moxeparvovec-rokl). ELEVIDYS is currently the only U.S. Food and Drug Administration (FDA)-approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD).
Scienmag
JUNE 17, 2025
Professor Marco Durante, a leading figure in the field of biophysics and heavy-ion therapy, has been honored with the European Research Council’s prestigious Advanced Grant. This award, designated for established scientists conducting groundbreaking research, will provide Professor Durante with multi-million euro funding to propel his ambitious project aimed at revolutionizing tumor therapy.
FDA Law
JUNE 18, 2025
By Mark A. Tobolowsky & Michelle L. Butler & Deborah L. Livornese — After teasing a new rapid review pilot program for the past few weeks, on June 17, 2025, FDA officially announced the Commissioner’s National Priority Voucher (“CNPV”) program to expedite new drug and biologic (but not device or drug-device combination product) reviews. As described in the press release and accompanying FAQ , the CNPV program is designed to reduce review time to 1-2 months following final drug applicati
Speaker: Amie Phillips Pablo, VP, Corporate Compliance & Privacy Officer at Novo Nordisk
In today’s complex healthcare environment, navigating third-party relationships has become even more challenging—whether it’s vendor relationships, employee activities, or patient-facing interactions. Left unmanaged, these conflicts can compromise trust, regulatory compliance, and even organizational reputation. So, how can healthcare teams stay ahead?
STAT News
JUNE 20, 2025
As former chairs of the CDC’s Advisory Committee on Immunization Practices ( ACIP ), we are deeply alarmed by the growing politicization of vaccines — a public health innovation that has saved 154 million lives globally. While politicization of science is not new, the escalating distrust in science across the political spectrum, and its intrusion into the vaccine ecosystem, now threatens the very infrastructure that has long protected Americans from infectious diseases.
The Pharma Data
JUNE 18, 2025
Merck Awards 2025 North American Advance Biotech Grant to Neoclease for AI-Driven Parkinson’s Gene Editing Therapy Merck, a global leader in science and technology, has officially named Neoclease as the recipient of its 2025 North American Advance Biotech Grant , recognizing the Boston-based biotech startup for its cutting-edge work in AI-designed gene-editing therapies, particularly targeting Parkinson’s disease.
Scienmag
JUNE 17, 2025
A Breakthrough in Taxol Biosynthesis: Unlocking the Enzymatic Blueprint for Scalable Cancer Drug Production Taxol, also known as paclitaxel, has stood as a cornerstone chemotherapy agent for decades, revolutionizing treatments for ovarian, breast, and lung cancers worldwide. Despite its critical role in oncology, the current approach to Taxol production faces substantial limitations.
NPR Health - Shots
JUNE 18, 2025
The study, published in JAMA, followed teens for years and evaluated addictive behaviors, as well as suicidality.
Advertisement
Download this comprehensive guide to AI and ML in the R&D Laboratory Setting.
Pharmaceutical Technology
JUNE 19, 2025
Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insigh
The Pharma Data
JUNE 18, 2025
Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D., to the role of Executive Vice President and Chief Research and Development Officer.
Scienmag
JUNE 20, 2025
A recent breakthrough cohort study published in JAMA Network Open has revealed critical insights into the intricate relationship between environmental burden and cancer incidence rates across diverse racial and ethnic populations. This comprehensive investigation emphasizes the pressing need for sustained and targeted community interventions, particularly in minoritized census regions characterized by elevated environmental stressors.
XTalks
JUNE 17, 2025
The FDA has approved Ibtrozi (taletrectinib) for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Developed by Nuvation Bio, taletrectinib is a next-generation oral tyrosine kinase inhibitor (TKI) designed to target cancers driven by ROS1 gene fusions. The fusions are more common in younger patients and those who have never smoked, and are frequently associated with brain metastases.
Expert insights. Personalized for you.
157 
Let's personalize your content